Kodiak Sciences (NASDAQ:KOD) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutics to treat high prevalence retinal diseases. Kodiak's flagship project involves creating novel biologics with the potential to provide durable, long-term efficacy with fewer injections for patients, addressing a significant unmet need in fields such as macular degeneration and diabetic eye diseases. The company's objective is to revolutionize retinal medicine and improve the lives of millions worldwide by advancing their pipeline of therapeutic candidates through clinical trials and bringing them to market.